Skip to main content
. Author manuscript; available in PMC: 2018 Feb 28.
Published in final edited form as: Sci Signal. 2017 Jan 31;10(464):eaaf7478. doi: 10.1126/scisignal.aaf7478

Fig. 4. AMPK increased HAT1 activity.

Fig. 4

HAT1 activity was assessed in cells treated with AICAR or metformin or left untreated. (A) AMPK+/+ and AMPK−/− MEFs. (B) AMPK−/− MEFs were infected with Ad-AMPK-CA or Ad-AMPK-DN AMPK (50 MOI) before treatment. n = 3 independent experiments for (A) and (B). (C) HAT1 activity in HUVECs transfected with control, AMPK, HAT1, or RBBP7 siRNA before the indicated treatment. n = 4 independent experiments. (D) HAT1 activity in cells transfected with control, AMPK, HAT1, or RBBP7 siRNA and then subjected to PSS. n = 3 independent experiments. (E and F) HUVECs were transfected with the indicated forms of HAT1 or RBBP7 and treated as indicated. n = 4 independent experiments for (E) and n = 3 independent experiments for (F). *P < 0.05.